Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(2)
•••
Comment by ANALIAS00on May 10, 2018 11:38am
99 Views
Post# 28011795

RE:RE:We are the only ones aware of these sales numbers

RE:RE:We are the only ones aware of these sales numbers
canadapiet wrote: How "inefficient" can a market be ????

GLTA 

PS: what a great BB for excellent info, wish there were more of that ......


All boards are ahead of the market, there is no exceptions.  All boards provide great info for great future of their stock.  All boards predicted a high SP of their stock.   
So all boards are exactly the same as this one.  The only exception is this one turned to be exactly right all the way from the beginning and continu to be ....    ;o)

And the day someone will say that the stock is overevaluated he will be accuse of shorting the stock ...   ;o)

Seriously, you guys did a super job finding and sharing all those info for us.  I was on the stock way before I find this board but for sure I add more shares than I would have without all your input.   So thanks again.     

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities